Mutants of herpes simplex virus type 1, resistant to phosphonoformate (PFA) and phosphonoacetate (PAA), have been selected in cell culture. The PFAresistant mutant (HSV-PFAr) and the PAA-resistant mutant (HSV-PAAr) were also resistant to PAA and PFA, respectively. This cross-resistance indicates that PFA and PAA interact at the same site. The HSV-PFAr had a decreased susceptibility to vidarabine, but no difference in sensitivity to idoxuridine (5-iodo-2'-deoxyuridine) was observed when compared to the wild type. The induced deoxyribonucleic acid polymerases isolated from cells infected with HSV-PFAr and HSV-PAAr were both cross-resistant to inhibition by PFA and PAA. No increased resistance to vidarabine triphosphate could be observed, but the susceptibility to inhibition by pyrophosphate was about two times lower. None of the mutants showed any increased temperature sensitivity Phosphonoformate (PFA) has been found to be active against herpesvirus replication in cell culture (5, 16) and to have a therapeutic effect on cutaneous herpes simplex virus (HSV) infection in guinea pigs (1, 5). The deoxyribonucleic acid (DNA) polymerase induced by HSV was inhibited by PFA, indicating that this was the mechanism of inhibition in the infected cell (5). Reno et al. (16) have reported that mutants of herpesvirus of turkeys resistant to phosphonoacetate (PAA) were also resistant to PFA. From a practical point of view it is important to establish how readily resistance develops to an antiviral drug and to know to what extent a mutant resistant to one inhibitor will be susceptible to other inhibitors. This information is also of interest in understanding the mechanism of inhibition. It has been suggested earlier (6) that the development of mutants resistant to an inhibitor is a good indication of a specific antiviral activity.
Phosphonoformate (PFA) has been found to be active against herpesvirus replication in cell culture (5, 16) and to have a therapeutic effect on cutaneous herpes simplex virus (HSV) infection in guinea pigs (1, 5) . The deoxyribonucleic acid (DNA) polymerase induced by HSV was inhibited by PFA, indicating that this was the mechanism of inhibition in the infected cell (5). Reno et al. (16) have reported that mutants of herpesvirus of turkeys resistant to phosphonoacetate (PAA) were also resistant to PFA. From a practical point of view it is important to establish how readily resistance develops to an antiviral drug and to know to what extent a mutant resistant to one inhibitor will be susceptible to other inhibitors. This information is also of interest in understanding the mechanism of inhibition. It has been suggested earlier (6) that the development of mutants resistant to an inhibitor is a good indication of a specific antiviral activity.
In this paper, the possibility to select HSV mutants resistant to PFA, the characteristics of these mutants, and their induced DNA polymerases have been investigated. Mutants resistant to PFA and the structurally related PAA (see Fig. 1 Chemicals. Vidarabine (9-/8-D-arabinofuranosyladenine monohydrate), vidarabine triphosphate, and idoxuridine (5-iodo-2'-deoxyuridine) were from Sigma Chemical Co., St Louis, Mo.; trisodium PFA and disodium PAA were synthesized according to Nyl6n (14) . Nucleoside triphosphates were from Sigma, and 3H-labeled deoxythymidine triphosphate was obtained from New England Nuclear Corp., Boston, Mass. Activated calf thymus DNA was prepared as described by Schlabach et al. (17) .
RESULTS
Development of mutants. The development of resistance for strain C 42 is shown in Table 1 for PFA and in Table 2 and that the susceptibility is the same as for virus at passage 0. The PFAr mutant of C 42 (passage VI) has a decreased susceptibility to vidarabine when compared to passage 0. A slight decrease in susceptibility to viderabine can also be seen for the PFA' strain 3/12 (passage VI).
Effects on the induced DNA polymerases. HSV DNA polymerases isolated from BHK cells infected with C 42 (PFAT and PAAr) were compared for their sensitivity to PFA and PAA. As shown in Fig. 2 the C 42-induced DNA polymerase activity was inhibited to 50% by 0.4 p&M PFA and 0.5 pM PAA. Figure 2 also (Table 6) .
Pyrophosphate, which is liberated from the individual nucleoside triphosphates during the polymerization process, also inhibited DNA polymerase activity, although at high concentra- (Table 6 ). DISCUSSION The selection of PFA' HSV mutants can be achieved in cell cultures and is an indication of the specificity of the inhibitor (6) . The ease of selecting resistant mutants (Tables 1 and 2 ) was similar for PFA and PAA and corresponds to earlier reports for PAA (3, 7, 11) and idoxuridine (2) . Resistance development seems, however, to be much easier in cell culture than in animals, qs reported for PAA (3) and idoxuridine (9), or found clinically with idoxuridine (8) . Preliminary evidence suggests less resistance development in animals to PFA (Alenius and Oberg, unpublished data).
Mutants resistant to PFA were resistant to PAA, indicating a similar mechanism of action ( Table 3 ). The PAA' mutants were also resistant to PFA (Tabel 3), confirming an earlier report by Reno et al. (16) on herpesvirus of turkeys. The PFA' mutants were susceptible to idoxuridine (Table 5) , but their susceptibility to vidarabine was decreased as compared to the wildtype virus (Table 5 ). The mechanism for this is unclear. It has been reported that PAA-resistant HSV infections in mice can be treated with vidarabine as effectively as the HSV wild type (11) . The animal models might not be so precise as to determine minor changes in drug resistance.
It has been found that one temperature-sensitive HSV mutant (ts D9) was also resistant to PAA and that the ratio of PFU at 39°C to PFU at 34°C was reported to be <2 x 10'5 (10). The PFAr and PAAF mutants selected in this work showed no significant increase in temperature sensitivity (Table 4) .
To verify the effect of PFA on the multiplication of HSV mutants in cells, herpesvirus DNA polymerases were prepared from wild-VOL. 15 (12) suggests that PAA interacts with the DNA polymerase at a pyrophosphate binding site. The decreased susceptibility to pyrophosphate observed for the mutants ( Table 6 ) also indicates that PFA affects the pyrophosphate binding site.
It has been reported that the mechansim of inhibition by PFA of the DNA polymerase from herpesvirus of turkeys is noncompetitive with respect to substrate and template (16) . The same mechanism of inhibition has been observed for DNA polymerase from HSV type 1 (B. Eriksson, unpublished data).
It was also evident ( Table 6 ) that the PFAresistant HSV DNA polymerase had the same sensitivity to vidarabine triphosphate as the wild-type polymerase. This means that the increased resistance to vidarabine observed for multiplication of PFAr mutants in cell culture might not be due to the mutated DNA polymerase. Development of thymidine kinase-negative mutants has been found during selection of PAA-resistant HSV mutants (7) .
The ease of selecting herpesvirus strains resistant to antiviral drugs in cell cultures might not be paralleled by such a rapid development clinically. It does, however, make it important to consider combinations of selective drugs acting with different mechanisms.
